A Mendelian blueprint for drug safety in pregnancy
A new Mendelian randomization study published in the International Journal of Gynecology & Obstetrics investigates the causal long-term health effects of gestational hypertension (GH). Using 149 genetic variants as instrumental variables, the analysis found no significant causal link between GH and a range of postpartum conditions, including mental and behavioral disorders, postpartum hemorrhage, puerperal sepsis, or depression. However, it identified a significant causal relationship, increasing the risk of stroke in women. The study found no evidence of a causal effect on other major diseases, including Alzheimer’s, severe depression, Parkinson’s, diabetes, or various cancers, with sensitivity analyses confirming the robustness of these findings against pleiotropic bias.
Why it might matter to you: For a pharmacologist focused on drug safety and therapeutic windows, this research highlights a critical long-term adverse outcome linked to a common pregnancy condition. It underscores the importance of considering cardiovascular risk in the post-marketing surveillance and pharmacovigilance of drugs used during pregnancy or that may affect blood pressure. The methodological use of Mendelian randomization offers a framework for investigating causal drug–disease relationships, which can inform the design of more targeted clinical trials and the development of safer therapeutic agents for at-risk populations.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
